Acorda stock: buy or sell?

ACOR stock price: $3.49 2.95% At close on September 20th, 2019

Updated on:
September 20th, 2019

1

Shares of Acorda Therapeutics ended today at $3.49 and jumped a very good 2.95%. On Tuesday ACOR collapsed a chilling -5.31%.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.

Should I buy Acorda stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Acorda stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ACOR will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Acorda Therapeutics stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we collected 12 ratings published for ACOR stock in the last 30 days.

Is ACOR a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-2Wedbushn/aNeutral
2019-8-2Wedbushn/aNeutral
2019-8-2Stifel Nicolausn/aHold
2019-8-2Cantor Fitzgeraldn/aNeutral
2019-8-14HC WainwrightBuyNeutral
2019-5-7JPMorgan Chase & Co.n/aHold
2019-2-15Cantor Fitzgeraldn/aHold
2019-1-4HC Wainwrightn/aBuy
2019-1-23HC Wainwrightn/aBuy
2019-1-2Oppenheimern/aHold
2019-1-2JPMorgan Chase & Co.n/aHold
2019-1-2Cantor Fitzgeraldn/aHold

Acorda stock analysis

Daily outlook

Acorda Therapeutics closed today at $3.49 and jumped a very good 2.95%.

Acorda Therapeutics shares jumped 2.95% to $3.49 today. ACOR is retaking the upward trend marking a new rising bottom heading to break out over $4.46.

ACOR stock chart (daily)

Weekly outlook

After boosting an exceptional 27.46% in a week last week, Acorda Therapeutics closed this week at $3.49 and plummed a hair-raising -9.59%.

Since price and 10-weeks moving average lines crossed down early February, ACOR fell $-13.09 per share (-78.95%).

ACOR stock chart (weekly)

Acorda stock price history

Acorda stock went public on February 10th, 2006 with a price of $6.171. Since then, ACOR stock declined a -43.40%, with a yearly average of -3.30%.

1: Adjusted price after possible price splits or reverse-splits.

Acorda stock historical price chart

ACOR stock reached 52-week highs on November at $21.63, and all-time highs 2015-01-13 with a price of 45.45.

Acorda stock price target is $17.50

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' ACOR stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 11 price targets for Acorda Therapeutics stock:
ACOR stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-2WedbushReiterates$8.00$7.00-12.5%
2019-8-2WedbushLowers Target$8.00$7.00-12.5%
2019-8-2Stifel NicolausLowers Target$12.00$7.00-41.7%
2019-8-2Cantor FitzgeraldLowers Target$20.00$12.00-40%
2019-8-14HC WainwrightDowngrades$31.00$6.00-80.6%
2019-5-7JPMorgan Chase & Co.Reiteratesn/a$18.00-
2019-2-15Cantor FitzgeraldReiteratesn/a$20.00-
2019-1-4HC WainwrightReiteratesn/a$33.00-
2019-1-23HC WainwrightSet Price Targetn/a$33.00-
2019-1-2OppenheimerSet Price Targetn/a$18.00-
2019-1-2Cantor FitzgeraldSet Price Targetn/a$32.00-
(in average)$15.80$17.5011.0%
Moving in a range from $33.00 and $6.00, the price target for ACOR stock is $17.50. In average, analysts' outlook on ACOR price forecast is positive, upgrading the prediction by a 11.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since February, when Acorda Therapeutics posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
ACOR earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.41n/a
2017-Q2-n/a-0.18n/a
2017-Q32017-10-310.650.43-33.8%
2017-Q42018-02-151.050.61-41.9%
2018-Q12018-05-020.33-0.18n/a
2018-Q22018-08-020.51.29158.0%
2018-Q32018-10-310.020.1400.0%
2018-Q42019-02-14-1.190.41n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual revenues report draw a scary loss of -19.86% to $471.43 million dollars. Nonetheless, its profit margin (compared to revenues) climbed to 7.14%, that is $33.68 million.

ACOR annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$336 M-$16 M4.9%-
2014$401 M19.34%$18 M4.4%7.49%
2015$493 M22.71%$11 M2.2%-37.43%
2016$520 M5.47%$-34.62 M-6.7%-413.06%
2017$588 M13.22%$-223.36 M-38.0%545.21%
2018$471 M-19.86%$34 M7.1%-115.08%

Quarterly financial results

Acorda Therapeutics posted $69.15 M in sales for 2018-Q4, a -51.58% decline compared to previous quarter. Reported quarter earnings marked $9.60 million with a profit margin of 13.88%. Profit margin rocketed a 23.62% compared to previous quarter when profit margin was -9.74%. When comparing revenues to same quarter last year, Acorda sales marked a bloodcurdling slide and plunged a -63.29%. Looking back to recent quarterly results, Acorda posted 2 negative quarters in a row.
ACOR quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$119 M-$-19 M-15.8%-
2017-Q2$139 M16.79%$-8 M-5.9%-56.61%
2017-Q3$141 M1.17%$-25 M-17.9%207.26%
2017-Q4$188 M33.55%$-171 M-90.8%578.96%
2018-Q1$106 M-43.65%$-8 M-7.7%-95.21%
2018-Q2$153 M44.40%$46 M30.1%-663.45%
2018-Q3$143 M-6.84%$-14 M-9.7%-130.11%
2018-Q4$69 M-51.58%$10 M13.9%-168.97%

Acorda ownership

When you are planning to invest in a stock, it's worth to check its ownership structure.

Acorda shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.85% of all shares.

Bearish positions for ACOR stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related companies:

ACORBMRNMNTAMYLRGEN
Market cap$167.9 M$13.5 B$1.3 B$10.8 B$4.2 B
Total shares48.1 M179.5 M98.7 M515.9 M51.5 M
Float shares39.5 M178.3 M93.7 M512.7 M47.0 M
  - Institutional holdings (%)112.3%102.9%98.0%86.2%91.6%
  - Insider holdings (%)1.8%0.4%2.1%1.1%10.2%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Acorda summary

Friday, September 20th, 2019
Open$3.39
Close$3.49
Day range$3.35 - $3.58
Previous close$3.39
Session gain2.95%
Average true range$0.39
50d mov avg$4.26
100d mov avg$6.64
200d mov avg$10.60
Daily patternlb02a
Weekly pattern lt03a

Acorda performance

To better understand Acorda Therapeutics performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Acorda Therapeutics to BioMarin Pharmaceutical, Momenta Pharmaceuticals, Mylan and Repligen:
Stock3m6m12m
ACORAcorda Therapeuti...-53.40%-73.42%-80.82%
BMRNBioMarin Pharmace...-14.74%-14.88%-23.40%
MNTAMomenta Pharmaceu...8.82%2.70%-50.48%
MYLMylan14.63%-26.80%-46.14%
RGENRepligen-0.76%39.89%49.19%

Acorda competitors

We chose a few stocks to conform a list of Acorda competitors to check if you are interested in investing in ACOR: